Marc Goodman
Stock Analyst at Leerink Partners
(3.58)
# 806
Out of 4,667 analysts
99
Total ratings
51.32%
Success rate
22.2%
Average return
Main Sectors:
Stocks Rated by Marc Goodman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven | Maintains: Outperform | $55 → $60 | $46.83 | +28.12% | 6 | Sep 23, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $32 | $33.91 | -5.63% | 1 | Apr 15, 2024 | |
| AMLX Amylyx Pharmaceuticals | Downgrades: Market Perform | n/a | $5.23 | - | 4 | Mar 11, 2024 | |
| BLTE Belite Bio | Initiates: Outperform | $25 | $82.53 | -69.71% | 1 | Jul 26, 2023 | |
| DNLI Denali Therapeutics | Initiates: Outperform | $50 | $24.42 | +104.75% | 1 | Jan 30, 2023 | |
| RLMD Relmada Therapeutics | Maintains: Outperform | $42 → $10 | $2.85 | +250.88% | 2 | Jan 23, 2023 | |
| MRNS Marinus Pharmaceuticals | Maintains: Outperform | $27 → $23 | $0.31 | +7,343.37% | 4 | Jan 23, 2023 | |
| EOLS Evolus | Maintains: Outperform | $18 → $20 | $12.63 | +58.35% | 3 | Jan 19, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $65 → $85 | $94.60 | -10.15% | 6 | Nov 29, 2022 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $100 → $115 | $123.29 | -6.72% | 4 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $310 | $156.00 | +98.72% | 11 | Oct 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $12 | $10.75 | +11.63% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $46 | $39.34 | +16.93% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $21 | $16.27 | +29.07% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $210 | $119.24 | +76.12% | 5 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $40 | $4.91 | +714.66% | 5 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $3.24 | +208.64% | 2 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $24 → $27 | $27.91 | -3.26% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $3.28 | +662.20% | 1 | Apr 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $70 | $85.64 | -18.26% | 3 | Apr 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $15 | $4.76 | +215.13% | 2 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $270 | $343.26 | -21.34% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $79 → $96 | $167.76 | -42.78% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $57.88 | - | 2 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $67 | $97.44 | -31.24% | 3 | Oct 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $98 | $27.15 | +260.96% | 7 | Oct 5, 2017 |
Biohaven
Sep 23, 2024
Maintains: Outperform
Price Target: $55 → $60
Current: $46.83
Upside: +28.12%
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: $32
Current: $33.91
Upside: -5.63%
Amylyx Pharmaceuticals
Mar 11, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $5.23
Upside: -
Belite Bio
Jul 26, 2023
Initiates: Outperform
Price Target: $25
Current: $82.53
Upside: -69.71%
Denali Therapeutics
Jan 30, 2023
Initiates: Outperform
Price Target: $50
Current: $24.42
Upside: +104.75%
Relmada Therapeutics
Jan 23, 2023
Maintains: Outperform
Price Target: $42 → $10
Current: $2.85
Upside: +250.88%
Marinus Pharmaceuticals
Jan 23, 2023
Maintains: Outperform
Price Target: $27 → $23
Current: $0.31
Upside: +7,343.37%
Evolus
Jan 19, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $12.63
Upside: +58.35%
Axsome Therapeutics
Nov 29, 2022
Maintains: Outperform
Price Target: $65 → $85
Current: $94.60
Upside: -10.15%
Neurocrine Biosciences
Nov 2, 2022
Maintains: Market Perform
Price Target: $100 → $115
Current: $123.29
Upside: -6.72%
Oct 26, 2022
Maintains: Outperform
Price Target: $270 → $310
Current: $156.00
Upside: +98.72%
Aug 11, 2022
Maintains: Outperform
Price Target: $6 → $12
Current: $10.75
Upside: +11.63%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $46
Current: $39.34
Upside: +16.93%
Aug 9, 2022
Maintains: Outperform
Price Target: $27 → $21
Current: $16.27
Upside: +29.07%
Aug 4, 2022
Maintains: Outperform
Price Target: $200 → $210
Current: $119.24
Upside: +76.12%
Jul 11, 2022
Maintains: Market Perform
Price Target: $50 → $40
Current: $4.91
Upside: +714.66%
Jul 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $3.24
Upside: +208.64%
Apr 28, 2022
Maintains: Market Perform
Price Target: $24 → $27
Current: $27.91
Upside: -3.26%
Apr 26, 2022
Initiates: Outperform
Price Target: $25
Current: $3.28
Upside: +662.20%
Apr 21, 2022
Maintains: Outperform
Price Target: $65 → $70
Current: $85.64
Upside: -18.26%
Dec 21, 2021
Maintains: Outperform
Price Target: $24 → $15
Current: $4.76
Upside: +215.13%
Mar 13, 2020
Maintains: Buy
Price Target: $300 → $270
Current: $343.26
Upside: -21.34%
Nov 19, 2019
Maintains: Buy
Price Target: $79 → $96
Current: $167.76
Upside: -42.78%
May 21, 2018
Downgrades: Neutral
Price Target: n/a
Current: $57.88
Upside: -
Oct 30, 2017
Maintains: Buy
Price Target: $72 → $67
Current: $97.44
Upside: -31.24%
Oct 5, 2017
Maintains: Buy
Price Target: $84 → $98
Current: $27.15
Upside: +260.96%